Amye J. Tevaarwerk, MD close
Amye J. Tevaarwerk, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Amye J. Tevaarwerk, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Amye Tevaarwerk, MD, obtained her medical degree from Washington University School of Medicine and completed an internship and residency in internal medicine at Barnes Jewish Hospital. Prior to entering clinical fellowship, she worked as a hospitalist for a year at Barnes Jewish Hospital in St. Louis. She completed a medical oncology fellowship at the University of Wisconsin. Her academic area of interest is breast oncology, with a focus on new drug development and women’s health issues as they relate to cancer survivorship. Dr. Tevaarwerk is a member of the UW Health Breast Center and part of Breast Disease-Oriented Working Group, through which multiple clinical trials in breast cancer are helping to find better treatments for those with cancer.


Medical Oncology

Breast Cancer

Breast Center


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Barnes-Jewish Hospital, St. Louis, MO
Internship Barnes-Jewish Hospital, St. Louis, MO
Medical School Washington University School of Medicine, St. Louis, MO

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Tevaarwerk’s research interests include breast oncology and Phase I clinical trials.

PubMed Articles
Tevaarwerk AJ Hocking WG Buhr KA Gribble M Seaborne LA Wisinski KB Burkard ME Yen T Wiegmann DA Sesto ME A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. Cancer . 2019 Mar 15;125(6):1000-1007
[PubMed ID: 30690714]
Morken CM Tevaarwerk AJ Swiecichowski AK Haine JE Williams ZT Norslien K Arroyo N Zhang X Campbell B Mendonca EA Juckett MB Sesto ME Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplantation Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. Biol Blood Marrow Transplant . 2019 Feb 11;
[PubMed ID: 30763727]
Donohue S Haine JE Li Z Trowbridge ER Kamnetz SA Feldstein DA Sosman JM Wilke LG Sesto ME Tevaarwerk AJ The Impact of a Primary Care Education Program Regarding Cancer Survivorship Care Plans: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. J Cancer Educ . 2019 Feb;34(1):154-160
[PubMed ID: 28932992]
Bines J Tevaarwerk AJ Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy. Cancer . 2019 Jan 15;125(2):181-184
[PubMed ID: 30500982]
Hua A Sesto ME Zhang X Wassenaar TR Tevaarwerk AJ Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice. J Cancer Educ . 2019 Jan 4;
[PubMed ID: 30610655]
Tevaarwerk AJ Klemp JR van Londen GJ Hesse BW Sesto ME Moving beyond static survivorship care plans: A systems engineering approach to population health management for cancer survivors. Cancer . 2018 Nov 15;124(22):4292-4300
[PubMed ID: 30277575]
Tevaarwerk AJ Sesto ME Continued Challenges to the Adoption and Implementation of Survivorship Care Plans. J Oncol Pract . 2018 Oct;14(10):573-576
[PubMed ID: 30192692]
Miller KD O'Neill A Gradishar W Hobday TJ Goldstein LJ Mayer IA Bloom S Brufsky AM Tevaarwerk AJ Sparano JA Le-Lindqwister NA Hendricks CB Northfelt DW Dang CT Sledge GW Jr Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol . 2018 Sep 1;36(25):2621-2629
[PubMed ID: 30040523]
Litzelman K Keller AO Tevaarwerk A DuBenske L Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. J Gen Intern Med . 2018 Jun;33(6):869-876
[PubMed ID: 29404942]
Huenerberg KJ Anderson BM Tevaarwerk AJ Neuman HB Wilke LG Seaborne LA Sesto M Integrating survivorship care planning in radiation oncology workflow. J Community Support Oncol . 2018 Mar-Apr;16(2):e66-e71
[PubMed ID: 30631797]
Yeruva SLH Zhao F Miller KD Tevaarwerk AJ Wagner LI Gray RJ Sparano JA Connolly RM E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer . 2018;4:1
[PubMed ID: 29354686]
Ma CX Suman V Goetz MP Northfelt D Burkard ME Ademuyiwa F Naughton M Margenthaler J Aft R Gray R Tevaarwerk A Wilke L Haddad T Moynihan T Loprinzi C Hieken T Barnell EK Skidmore ZL Feng YY Krysiak K Hoog J Guo Z Nehring L Wisinski KB Mardis E Hagemann IS Vij K Sanati S Al-Kateb H Griffith OL Griffith M Doyle L Erlichman C Ellis MJ A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. Clin Cancer Res . 2017 Nov 15;23(22):6823-6832
[PubMed ID: 28874413]
Donohue S Haine JE Li Z Feldstein DA Micek M Trowbridge ER Kamnetz SA Sosman JM Wilke LG Sesto ME Tevaarwerk AJ Cancer Survivorship Care Plan Utilization and Impact on Clinical Decision-Making at Point-of-Care Visits with Primary Care: Results from an Engineering, Primary Care, and Oncology Collaborative for Survivorship Health. J Cancer Educ . 2017 Nov 2;
[PubMed ID: 29098650]
Tevaarwerk AJ Hocking WG Zeal JL Gribble M Seaborne L Buhr KA Wisinski KB Burkard ME Wiegmann DA Sesto ME Accuracy and Thoroughness of Treatment Summaries Provided as Part of Survivorship Care Plans Prepared by Two Cancer Centers. J Oncol Pract . 2017 May;13(5):e486-e495
[PubMed ID: 28221896]
Mirrielees JA Breckheimer KR White TA Denure DA Schroeder MM Gaines ME Wilke LG Tevaarwerk AJ Breast Cancer Survivor Advocacy at a University Hospital: Development of a Peer Support Program with Evaluation by Patients, Advocates, and Clinicians. J Cancer Educ . 2017 Mar;32(1):97-104
[PubMed ID: 26477478]
Rampurwala M Wisinski KB Burkard ME Ehsani S O'Regan RM Carmichael L Kim K Kolesar J Tevaarwerk AJ Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs . 2017 Feb;35(1):87-94
[PubMed ID: 27826831]
Tevaarwerk AJ Wisinski KB O'Regan RM Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. J Oncol Pract . 2016 Nov;12(11):1148-1156
[PubMed ID: 27858538]
Neuman HB Jacobs EA Steffens NM Jacobson N Tevaarwerk A Wilke LG Tucholka J Greenberg CC Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care. Cancer Med . 2016 Sep;5(9):2198-204
[PubMed ID: 27356781]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer . 2016 Aug;16(4):256-61
[PubMed ID: 27133732]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res . 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]